Search

Your search keyword '"PERRY, Chava"' showing total 5 results
Start Over Author "PERRY, Chava" Journal american journal of hematology
5 results on '"PERRY, Chava"'

1. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “ Real‐World ” study

Author

Levi, Shai, primary, Bronstein, Yotam, additional, Goldschmidt, Neta, additional, Morabito, Fortunato, additional, Ziv‐Baran, Tomer, additional, Del Poeta, Giovanni, additional, Bairey, Osnat, additional, Del Principe, Maria Ilaria, additional, Fineman, Riva, additional, Mauro, Francesca Romana, additional, Gutwein, Odit, additional, Reda, Gianluigi, additional, Ruchlemer, Rosa, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Shvidel, Lev, additional, Coscia, Marta, additional, Tadmor, Tamar, additional, Varettoni, Marzia, additional, Aviv, Ariel, additional, Murru, Roberta, additional, Braester, Andrei, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Zucchetto, Antonella, additional, Bomben, Riccardo, additional, Olivieri, Jacopo, additional, Neri, Antonio, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Trentin, Livio, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Perry, Chava, additional, Gattei, Valter, additional, Gentile, Massimo, additional, and Herishanu, Yair, additional

Published
2022
Full Text
View/download PDF

2. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group

Author

Herishanu, Yair, primary, Shaulov, Adir, additional, Fineman, Riva, additional, Bašić‐Kinda, Sandra, additional, Aviv, Ariel, additional, Wasik‐Szczepanek, Ewa, additional, Jaksic, Ozren, additional, Zdrenghea, Mihnea, additional, Greenbaum, Uri, additional, Mandac, Inga, additional, Simkovic, Martin, additional, Morawska, Marta, additional, Benjamini, Ohad, additional, Spacek, Martin, additional, Nemets, Anatoly, additional, Bairey, Osnat, additional, Trentin, Livio, additional, Ruchlemer, Rosa, additional, Laurenti, Luca, additional, Stanca Ciocan, Oana, additional, Doubek, Michael, additional, Shvidel, Lev, additional, Dali, Nagib, additional, Mirás, Fátima, additional, De Meûter, Anne, additional, Dimou, Maria, additional, Mauro, Francesca R., additional, Coscia, Marta, additional, Bumbea, Horia, additional, Szász, Róbert, additional, Tadmor, Tamar, additional, Gutwein, Odit, additional, Gentile, Massimo, additional, Scarfò, Lydia, additional, Tedeschi, Alessandra, additional, Sportoletti, Paolo, additional, Gimeno Vázquez, Eva, additional, Marquet, Juan, additional, Assouline, Sarit, additional, Papaioannou, Maria, additional, Braester, Andrei, additional, Levato, Luciano, additional, Gregor, Michael, additional, Rigolin, Gian M., additional, Loscertales, Javier, additional, Medina Perez, Angeles, additional, Nijziel, Marten R., additional, Popov, Viola M., additional, Collado, Rosa, additional, Slavutsky, Irma, additional, Itchaki, Gilad, additional, Ringelstein, Shimrit, additional, Goldschmidt, Neta, additional, Perry, Chava, additional, Levi, Shai, additional, Polliack, Aaron, additional, and Ghia, Paolo, additional

Published
2020
Full Text
View/download PDF

3. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study

Author

Perry, Chava, primary, Ben Barouch, Sharon, additional, Goldschmidt, Neta, additional, Sarid, Nadav, additional, Herishanu, Yair, additional, Shvidel, Lev, additional, Bairey, Osnat, additional, Lavi, Noa, additional, Horowitz, Netanel, additional, Avigdor, Avraham, additional, Lebel, Eyal, additional, Sofer, Orit, additional, Ram, Ron, additional, and Avivi, Irit, additional

Published
2019
Full Text
View/download PDF

5. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.

Author

Levi S, Bronstein Y, Goldschmidt N, Morabito F, Ziv-Baran T, Del Poeta G, Bairey O, Del Principe MI, Fineman R, Mauro FR, Gutwein O, Reda G, Ruchlemer R, Sportoletti P, Laurenti L, Shvidel L, Coscia M, Tadmor T, Varettoni M, Aviv A, Murru R, Braester A, Chiarenza A, Visentin A, Pietrasanta D, Loseto G, Zucchetto A, Bomben R, Olivieri J, Neri A, Rossi D, Gaidano G, Trentin L, Foà R, Cuneo A, Perry C, Gattei V, Gentile M, and Herishanu Y

Subjects
Humans, Rituximab therapeutic use, Cyclophosphamide therapeutic use, Vidarabine therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results